Financial Data and Key Metrics Changes - The company reported revenue of $218.1 million, representing a 13% year-over-year increase [8][23] - Adjusted EBITDA was $10.8 million, with a margin of 4.9%, improving more than 3.5 times compared to the same quarter last year [9][29] - The net loss was $11.1 million, compared to a net loss of $6.2 million in the same quarter last year [28] Business Line Data and Key Metrics Changes - Census grew to approximately 7,530 participants, reflecting a 10% annual increase [9][11] - Center level contribution was $40.7 million, with an 18.7% margin, improving by approximately 110 basis points year-over-year [8][26] - External provider costs were $107.9 million, a 7.9% increase year-over-year, but cost per participant decreased [24][25] Market Data and Key Metrics Changes - The increase in member months was primarily due to growth in existing California and Colorado centers, along with new centers in Florida [23][24] - The company experienced a modest sequential growth due to seasonal headwinds during Medicare's Annual Enrollment Period [11][12] Company Strategy and Development Direction - The company is focused on operational excellence and building a scalable, tech-enabled platform for sustainable growth [10][18] - There is an emphasis on integrating pharmacy services into the clinical model to improve medication adherence and reduce costs [17][18] - The company is actively engaging with policymakers to advocate for the PACE model, which is seen as a high-value solution for seniors [7][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate policy uncertainties and maintain operational predictability [19][20] - The company reaffirmed its fiscal year 2025 guidance, expecting ending census between 7,750 and 7,850 participants [31] Other Important Information - The company has made strategic progress in its pharmacy initiative, successfully transitioning to in-house pharmacy services [17] - There was a significant increase in corporate general and administrative expenses due to the accrual of a stockholder lawsuit settlement [27][28] Q&A Session Summary Question: Initial 2026 guidance and Medicare/Medicaid rate development - Management indicated that it is early for 2026 guidance but expects reasonable Medicare rates and some positive indications for Medicaid rates [34][36][39] Question: Changes in pharmacy utilization trends - Management noted no significant changes in pharmacy utilization trends, emphasizing that their reimbursement model differs from traditional Medicare Advantage [40][41] Question: Engagement with regulators regarding PACE - Management highlighted increased engagement with regulators, focusing on the value of PACE and the populations served [44][45][48] Question: De novo losses and enrollment trends - Management confirmed that de novo losses are tracking with expectations and that census growth is consistent with projections [66][71] Question: Cost of care and investments - Management discussed investments in insourcing services and the impact on cost of care, indicating a potential for normalized growth rates moving forward [72][75]

Financial Data and Key Metrics Changes - The company reported revenue of $218.1 million, representing a 13% year-over-year increase from $193.1 million in the same quarter last year [8][23] - Adjusted EBITDA was $10.8 million, with a margin of 4.9%, significantly improving from $3 million in the third quarter of fiscal year 2024 [9][30] - The net loss for the quarter was $11.1 million, compared to a net loss of $6.2 million in the same quarter last year [29] Business Line Data and Key Metrics Changes - Census grew to approximately 7,530 participants, reflecting a 10% annual increase [10][23] - Center level contribution was $40.7 million, with an 18.7% margin, improving by approximately 110 basis points year-over-year [8][27] - External provider costs were $107.9 million, a 7.9% increase compared to the same quarter last year, driven by an increase in member months [25][26] Market Data and Key Metrics Changes - The increase in member months was primarily due to growth in existing California and Colorado centers, along with new centers in Florida [24] - The company experienced a modest sequential growth in census due to seasonal headwinds during Medicare's Annual Enrollment Period [12] Company Strategy and Development Direction - The company is focused on operational excellence and greater organizational efficiency, aiming to build a scalable, tech-enabled platform for sustainable growth [11][19] - The transformation efforts are described as more ambitious than previous improvement initiatives, with a comprehensive approach to reimagine operations and value creation [11][20] - The company is actively engaging with policymakers to advocate for the PACE model, emphasizing its value for seniors and the healthcare system [7][47] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate a healthcare environment marked by policy uncertainty, reaffirming fiscal year 2025 earnings guidance [6][33] - The company is optimistic about the long-term value of the PACE model, which is seen as resilient in uncertain policy environments [20][21] - Management highlighted the importance of maintaining strong cost discipline while delivering quality outcomes for participants [14][19] Other Important Information - The company has successfully integrated pharmacy services into its clinical model, which is expected to enhance medication adherence and reduce costs [18] - The flu vaccination rate for participants is reported at 77%, significantly above the national average for seniors [15] Q&A Session Summary Question: Initial 2026 guidance and Medicare/Medicaid rate development - Management indicated that it is early for 2026 guidance but expects reasonable Medicare rates and some positive indications for Medicaid rates [36][38] Question: Changes in pharmacy utilization trends - Management noted no significant changes in pharmacy utilization trends, emphasizing that their reimbursement model differs from traditional Medicare Advantage [42][43] Question: Engagement with regulators regarding PACE - Management confirmed increased engagement with regulators, focusing on the value of PACE and the populations served, while addressing potential risks related to eligibility and state budgets [46][49] Question: De novo losses and enrollment trends - Management reported that de novo losses are tracking with expectations, with positive momentum in new markets [66][68] Question: Cost of care and investments - Management acknowledged increased costs due to insourcing certain services but expects a more normalized growth rate going forward [73][75]

Core Viewpoint - InnovAge Holding Corp. reported strong revenue growth but faced increased losses in its fiscal third quarter ended March 31, 2025, indicating challenges in cost management despite a growing participant base [2][3]. Financial Results - Total revenues for the third quarter reached $218.1 million, a 13.0% increase from $193.1 million in the same quarter of the previous year [3][22]. - Loss Before Income Taxes was $11.1 million, up 72.6% from a loss of $6.4 million in the prior year [3][22]. - Net loss was $11.1 million, compared to a net loss of $6.2 million in the same quarter of the previous year, with a net loss margin of 5.1%, an increase of 1.9 percentage points [3][22]. - Adjusted EBITDA was $10.8 million, significantly up from $3.0 million in the same quarter of the previous year, with an adjusted EBITDA margin of 4.9% [3][22]. Operational Metrics - The company served approximately 7,530 participants, an increase from 6,820 participants in the same quarter of the previous year [3][10]. - Center-level Contribution Margin was $40.7 million, a 19.9% increase compared to $34.0 million in the same quarter of the previous year [3][22]. Cash and Debt Position - As of March 31, 2025, InnovAge had $60.5 million in cash and cash equivalents and $41.3 million in short-term investments, with total debt of $77.3 million [3][19]. Full Fiscal Year 2025 Financial Guidance - The company expects total revenues for the fiscal year to be between $815 million and $865 million, with adjusted EBITDA projected between $24 million and $31 million [5][6]. Leadership Changes - Dr. Richard Feifer, the Chief Medical Officer, departed the company effective April 25, 2025, to pursue other opportunities [4].

Core Insights - Ensign Group (ENSG) reported revenue of $1.17 billion for Q1 2025, marking a year-over-year increase of 16.1% and a slight surprise of +0.23% over the Zacks Consensus Estimate [1] - The earnings per share (EPS) for the same quarter was $1.52, compared to $1.30 a year ago, resulting in an EPS surprise of +1.33% against the consensus estimate of $1.50 [1] Financial Performance Metrics - Actual patient days were reported at 2,538,135, slightly below the average estimate of 2,554,506 from two analysts [4] - Rental revenue was $6 million, compared to the average estimate of $6.60 million from two analysts [4] - Skilled services revenue was reported at $1.12 billion, matching the average estimate from two analysts [4] - Total service revenue was $1.17 billion, slightly above the average estimate of $1.16 billion from two analysts [4] Stock Performance - Ensign Group's shares have returned -1.8% over the past month, while the Zacks S&P 500 composite has seen a -0.8% change [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [3]

Company Overview - Alignment Healthcare, Inc. is focused on providing high-quality, low-cost care for its Medicare Advantage members, emphasizing a mission-driven approach to senior care [2] - The company utilizes a customized care model, a 24/7 concierge care team, and proprietary technology named AVA to deliver coordinated care [2] - Alignment Healthcare is based in California and partners with nationally recognized local providers to enhance its service offerings [2] Upcoming Events - Alignment Healthcare will present at the BofA Securities Healthcare Conference on May 14, 2025, at 2:20 p.m. PDT [1] - A webcast and replay of the presentation will be accessible on the company's investor relations website [1]

Core Viewpoint - InnovAge Holding Corp. is set to release its fiscal third quarter financial results for 2025 on May 6, 2025, after market close, followed by a conference call to discuss the results [1]. Group 1: Company Overview - InnovAge is a leader in providing comprehensive healthcare programs for frail, predominantly dual-eligible seniors through the PACE model [3]. - The company's mission focuses on enabling older adults to age independently in their homes while improving care quality and reducing high-cost care utilization [3]. - As of December 31, 2024, InnovAge served approximately 7,480 participants across 20 centers in six states [3]. Group 2: Conference Call Details - A live audio webcast of the conference call will be available on the company's website, with a replay accessible shortly after the call [2]. - Participants are encouraged to join the call fifteen minutes prior to the scheduled start time [2].

MARKHAM, Ontario, April 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare" or the "Company") (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company (the "Common Share") for the month of April 2025, which is payable on May 15, 2025 to shareholders of record at the close of business on April 30, 2025. This dividend is designated as an "eligible dividend" within the meaning of the Income Tax Act (Canada). About Extendicare Extendicare is a leading provide ...

Company Overview - Extendicare Inc. is a leading provider of care and services for seniors across Canada, operating under various brands including Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Network [2] - The company operates a network of 122 long-term care homes, with 51 owned and 71 under management contracts [2] - Extendicare delivers approximately 11.0 million hours of home health care services annually and provides group purchasing services to third parties representing around 146,300 beds across Canada [2] - The company employs approximately 24,000 qualified and dedicated team members focused on delivering high-quality care and services [2] Recent Financial Announcement - Extendicare has declared a cash dividend of C$0.042 per common share for March 2025, payable on April 15, 2025, to shareholders of record as of March 31, 2025 [1]